share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 13 15:40
Summary by Moomoo AI
Cybin Inc., a clinical-stage biopharmaceutical company, announced it will host a conference call and webcast on March 13, 2024, to provide an update on CYB003, its deuterated psilocybin analog in development for the treatment of Major Depressive Disorder (MDD). The update will include 4-month durability data from the Phase 2 trial of CYB003. Cybin's CEO Doug Drysdale and Chief Medical Officer Amir Inamdar will be the speakers at the event. The company, which is committed to developing innovative psychedelic-based treatments for mental health conditions, is also working on CYB004, a deuterated DMT molecule for generalized anxiety disorder, and has a pipeline of investigational compounds. The webcast will be available on Cybin's investor relations website.
Cybin Inc., a clinical-stage biopharmaceutical company, announced it will host a conference call and webcast on March 13, 2024, to provide an update on CYB003, its deuterated psilocybin analog in development for the treatment of Major Depressive Disorder (MDD). The update will include 4-month durability data from the Phase 2 trial of CYB003. Cybin's CEO Doug Drysdale and Chief Medical Officer Amir Inamdar will be the speakers at the event. The company, which is committed to developing innovative psychedelic-based treatments for mental health conditions, is also working on CYB004, a deuterated DMT molecule for generalized anxiety disorder, and has a pipeline of investigational compounds. The webcast will be available on Cybin's investor relations website.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more